Huang HY |
------>authors3_c= ------>paper_class1=1 ------>Impact_Factor=2.945 ------>paper_class3=2 ------>paper_class2=1 ------>vol=17 ------>confirm_bywho=sihuang ------>insert_bywho=sihuang ------>Jurnal_Rank=18.2 ------>authors4_c= ------>comm_author=1 ------>patent_EDate=None ------>authors5_c= ------>publish_day=1 ------>paper_class2Letter=None ------>page2=517 ------>medlineContent= ------>unit=J0400 ------>insert_date=20060104 ------>iam=7 ------>update_date=None ------>author=??? ------>change_event=4 ------>ISSN= ------>authors_c= ------>score=500 ------>journal_name=Journal of Nutritional Biochemistry ------>paper_name=One-Year Soy Isoflavone Supplementation Prevents Early Postmenopausal Bone Loss but Without a Dose-Dependent Effect ------>confirm_date=20070901 ------>tch_id=085004 ------>pmid=16563719 ------>page1=509 ------>fullAbstract=It is believed that soy isoflavone has much potential effectiveness on the postmenopausal status; however, the optimal dose for preventing postmenopausal bone loss still remains unclear. This open-labeled, self-controlled pilot study was undertaken to determine the effect of 1-year supplementation of different high dosages of soy isoflavone in postmenopausal Taiwanese women. Forty-three women aged 45-67 years were enrolled and randomly assigned into a control (C), 100 mg/day isoflavone (IF100) and 200 mg/day isoflavone (IF200) groups for 1 year. Dual-energy X-ray absorptiometry and other related biochemical markers of bone metabolism were measured. Results indicated that the decrease in bone mineral density (BMD) was significant for lumbar vertebrae L1-3, L1-4 and the femur neck in the C group; surprisingly, the BMD of L1-3 was significantly elevated in the IF100 group; however, there were no consistent responses in the IF200 group. No significant change except loss of the bone mineral content of Ward~s triangle (P=.003) was found in the IF200 group after treatment. The percentage change at L1-3 was less (P=.04) in the IF200 group when compared to the IF100 group. A relatively uniform direction of bone formation in expanding the weight and area with different rates of change resulted in different BMD changes. Both indicated a change of bone formation patterns with the higher-dose supplement. A protective effect of IF100 on estrogen-related bone loss was observed. A lack of a benefit such as high safety in the IF200 group for 1-year administration was ensured and lacked undesirable side effects. ------>tmu_sno=None ------>sno=12404 ------>authors2=Yang HP ------>authors3=Yang HT ------>authors4=Yang TC ------>authors5=Shieh MJ ------>authors6=Huang SY ------>authors6_c= ------>authors=Huang HY ------>delete_flag=0 ------>SCI_JNo=None ------>authors2_c= ------>publish_area=0 ------>updateTitle=One-year soy isoflavone supplementation prevents early postmenopausal bone loss but without a dose-dependent effect. ------>language=2 ------>check_flag=None ------>submit_date=None ------>country=None ------>no=8 ------>patent_SDate=None ------>update_bywho=None ------>publish_year=2006 ------>submit_flag=None ------>publish_month=1 |